Get started
Asc triangle moving up, with prior track record UK stockAsc triangle moving up, with prior track record UK stock height of triangle gives target, long term chart, confirmation given by UK FTSE also moving up, also European indices eg MIB moving up. Reliable steady stock Enter using limit orders on any pull backs to top of triangle Stop out if price re enters triangle Target trailing stop, take 85% at target, which becomes the new stop Look to build position using multiple limit orders for entry on market down days, add if the pattern pauses making smaller time period patterns Have fun!
LSE:COALong
by William_Playfair
CMC Markets found substantial support at 100GBXCMC markets hit a 3-year low of 100GBX after news of lower revenue expectations but found huge support at the level with an immediate jump of 16% in 2 trading days. Fundamentally, CMC is trading at around 1X revenue. Given that CMC is a global, established, and profitable company, with consistent growth in its customer base. I think that the 100 GBX price was a bottom where reversal is taking place. I expect the price to reach 220-270 GBX at around the next dividend payment at the end of November-beginning of December. Not financial advice. Do your own research.
LSE:CMCXLong
by notalireza
Breakout After multiple attempts at failing to break the blue resistance line price has closed strongly above this level today. The catalyst for this was the release of good results, check them out for yourself. In addition to this they have just got approval from their Spanish business for $5 billion. Ker-ching. They have also announced a £500 million share buyback program. Also of note is that two of the Directors have recently bought large chunks of stock. One bought £1.5 million worth the other over £0.5 million. Dividend yield %10. Winner, winner, chicken dinner !
LSE:VOD
by RIckAshby
3
BATS RSI Divergence, EMA targets and Support/Resistance Zones BATS is a company where its financial performance and robustness is not reflected by it's share price, mainly owing to investor sentiment towards the sector it sits within and the fear of ever changing regulation of its products. It is currently generating £8.5bn in free cash flow, more than enough to pay the annual dividend and please any accountant that the company's operations still produces high margin returns (although this is less obvious in the accounts due to the non-cash impairment of its assets). From a technical stand point the chart depicts a favourable time to enter into BATS, with price currently consolidating at a weekly demand zone. Furthermore, there has been a clear divergence between price and the RSI which has been growing over the last year. The longer these build, the higher probability of a sharp reversal. The crossing of the 20 and 50 EMA on the weekly chart has been a trustworthy indicators of changes in trend, with gap between these two MAs beginning to close. I am expecting price to move sharply towards the 100EMA and short term supply zone at £26.80, resulting in the crossing of the 20/50 EMA, which will propel the price towards the first significant supply zone at £32. From here there will be a final push before the end of the year with the price testing the 5 year high. All this will happen in an impulsive 5 wave pattern. If £22 is retested and fails to hold as support than the likelihood is for further declines. As an investor, stop losses should be set at £21.50 and profits should be taken at £36, representing a risk to reward of 7.4. Disclaimer: I entered into a position here on 7th May 2024
LSE:BATSLong
by Doddle
1
FTSE's Pharma Surge: A Closer Look at Leading StocksThe FTSE 100’s recent surge has been led by the pharmaceutical sector, marking a 13.7% increase in just the last month. Let’s delve into the standout performers that are leading the rally. AstraZeneca (AZN): +14.5% YTD AstraZeneca’s share price jumped higher following the release of a market-beating set of results… In the first quarter of 2024, AstraZeneca performed exceptionally well, surpassing analysts’ expectations with a 19% growth in revenue. This impressive growth was primarily driven by increased sales of its cancer drugs. The pharma giant reported a revenue of $12.7 billion, significantly outperforming consensus estimates, which had projected $11.9 billion. AstraZeneca also reiterated its guidance for the current year, expecting double-digit growth in both sales and earnings. On the price chart, the shares have now moved into a key area of resistance which represent the April 2023 all-time highs. Momentum traders will be watching closely for a break and close above this resistance as it could trigger AstraZeneca’s next trend leg higher. AZN Daily Candle Chart Past performance is not a reliable indicator of future results GlaxoSmithKline (GSK): +21.1% YTD Like AstraZeneca, GSK's share price has been buoyed by a strong set of first-quarter results… GSK’s recent trading statement showed improvements across various metrics, with revenue increasing by 10% to £7.4 billion and underlying operating profit rising by 27% to £2.4 billion, driven by robust growth in Vaccines and Speciality medicines. GSK's momentum from last year has continued into 2024, driven by strong financial performance and supported by excellence in research & development, which resulted in four major product approvals last year. Vaccines have emerged as a key growth driver, particularly with products like Shingrix and the recently approved RSV vaccine, Arexvy. The company's focus on HIV treatments and the shift towards long-acting innovation therapies has also contributed to growth in this segment. On the price chart, GSK is showing strong upwards momentum with the shares breaking above swing resistance at the start of this month. However, the July 2022 cluster of swing highs should provide some resistance in the coming weeks. GSK Daily Candle Chart Past performance is not a reliable indicator of future results Hikma Pharmaceuticals (HIK): +11.3% YTD Relative to AstraZeneca and GSK, Hikma has been a laggard with prices chopping sideways within a long-term wedge pattern (see chart below). That said, recent price action saw the shares print a large bullish reversal pattern following a market-beating trading statement… Hikma reported a 30% increase in profit, reaching $367 million last year, with revenue hitting $2.875 billion, up by 14% from the previous year. The core business saw operating profit up by 19%, mainly due to better profitability in both branded and generic segments. Generics experienced strong growth, with revenue up by 39% and core operating profit up by 86%. However, the company expects profits to be slightly lower in 2024 compared to last year. We are starting to see sector laggards like Hikma picking up momentum as the front runners, AZN and GSK move towards resistance. This indicates that the FTSE’s Pharma rally may be entering into the final phases. HIK Daily Candle Chart Past performance is not a reliable indicator of future results Disclaimer: This is for information and learning purposes only. The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance. Social media channels are not relevant for UK residents. Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.84% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
LSE:AZN
by Capital.com
GLENCORE Analysis - Continuous, Just as the Markets !This is a Thread, so Follow for Technical Analysis performed with TrapZone Pro & UMVD Indicators. * Trend is Based on TrapZone Color * Bar Colors give us Momentum Green from strong Up Moves. Red Bars point to strong Down Moves. * Red UMVD = Selling Pressure & Green UMVD = Buying Pressure. Purple is for Divergence = Battle of Supply & Demand -------------------- 1-23-2024 Strong downtrend with RED TrapZone established for days now. Price retraces with GREEN UMVD but the effect is not the same as RED UMVD - Obviously. Price is retracing a bit again with GREEN UMVD coming in now.
LSE:GLEN
by SnowflakeTrader
3
Will Aston Martin return to its former glory ? LSE:AML Aston Martin shares are down around 35% since the beginning of 2024. Shares continues to decline since august 2023 what´s around another 30% (65% from august 2023 till now). Aston Martin shares don´t look fresh even from wider perspective as you can see the historic chart. Company itself has occurred in kind of transition since Lawrence Stroll became executive chairman in early 2020 with 16,7% stake in the company. Moreover he re-branded F1 team Racing Point as the Aston Martin F1 Team in 2021. He´s really into it. Briefly about Aston Martin F1 Team 🏎️: - Lawrence Stroll´s given his son every opportunity to become an F1 driver. He became a stable part of F1 - Stroll said Aston Martin sees its first victory in F1 this year - building new Aston Martin factory Company signed new CEO Adrian Hallmark as a part of transition. Former Chairman and CEO of Bentley Motors will replace Amedeo Felisa no later than 1st October 2024. Aston Martin also announced the delivery of four new models in 2024 (Vantage, upgraded DBX707, V12 flagship sports car and more) which would power growth in the second half of the year and beyond. All these news sounds good. ✔️ However the finances don´t look so great. Aston Martin´s still BLEEDING. 💉 - widening losses in the first quarter due to stopped production of its core models ahead of a launch a new vehicles - revenue fell 10% to 267.7£ - debt increased 20% to 1.04£ - wholesale volumes slumped by 35% in Americas, by 30% in the U.K., by 14% in Asia-Pacific and by 17% in the wider Europe, ME and Africa region Will Aston Martin shine again ? Well, it seems that only time will tell us whether they´ll succeed Fun fact: Aston Martin officially opened new "Aston Martin Residences Miami", an ultra-luxury brand´s first real estate project. You can read more about the project at official Aston Martin page. Sources: cnbc.com astonmartin.com
LSE:AML
by n1performer
1
AHT - 13 months RECTANGLE══════════════════════════════ Since 2014, my markets approach is to spot trading opportunities based solely on the development of CLASSICAL CHART PATTERNS 🤝Let’s learn and grow together 🤝 ══════════════════════════════ Hello Traders ✌ After a careful consideration I came to the conclusion that: - it is crucial to be quick in alerting you with all the opportunities I spot and often I don't post a good pattern because I don't have the opportunity to write down a proper didactical comment; - since my parameters to identify a Classical Pattern and its scenario are very well defined, many of my comments were and would be redundant; - the information that I think is important is very simple and can easily be understood just by looking at charts; For these reasons and hoping to give you a better help, I decided to write comments only when something very specific or interesting shows up, otherwise all the information is shown on the chart. Thank you all for your support 🔎🔎🔎 ALWAYS REMEMBER "A pattern IS NOT a Pattern until the breakout is completed. Before that moment it is just a bunch of colorful candlesticks on a chart of your watchlist" ═════════════════════════════ ⚠ DISCLAIMER ⚠ The content is The Art Of Charting's personal opinion and it is posted purely for educational purpose and therefore it must not be taken as a direct or indirect investing recommendations or advices. Any action taken upon these information is at your own risk.
ALong
by TheArtOfCharting
Darktrace. When will it be a FTSE 100 stock ?Cybersecurity company Darktrace has had a fantastic run recently. The company have recently raised profit forecasts and a number of brokers have raised the price target for the share price, one analyst is forecasting £8.00 from memory. Looking at the current market cap, Darktrace is 3.21B. Compare this to Ocado, who are at present in the FTSE 100 .Their market cap currently stands at 2.853B. If Darktrace became a FTSE constituent then tracker funds would need to buy in. Excellent technical analysis by previous posts. What do you guys think now ?
D
by RIckAshby
2
Will it bounce ?Ocado Group has been a terrible stock to hold as any long term investor knows only too well. Price is currently £3.50, back to the level last seen June 2023. As can be seen on the chart the price rallied strongly from this point. The 4hr candle chart has just posted a bullish engulfing pattern, it must be noted the ftse is currently up 60 points and change. Ocado currently up 2%. The Trading View standard rsi divergence indicator has also given a buy signal. May be worth a nibble ?
LSE:OCDO
by RIckAshby
2
Top 20 Tips for 2021Please find a portfolio of 20 shares that I have assembled that I believe can perform very well. Please also note that this is the first time I am doing this portfolio on trading view and it is currently a prototype. The companies are listed in no particular order. 1. Hollywood bowl 2. Atalaya mining 3. ASOS 4. AMD 5. Royal Dutch Shell B 6. Ferrexpo 7. Hunting 8. Whitbread 9. Crystal Amber 10. Savannah resources 11. Centamin 12. Barclays 13. Aviva 14. Just group 15. Standard chartered 16. Anglo American 17. Ten entertainment 18. Avon protection 19. Redrow 20. Impact healthcare REIT Please note: The prices will be published at the end of the trading session
LSE:BOWL
by hammochess
2
Future PLC: A Compelling Buy with a Bright OutlookIn the ever-evolving landscape of digital publishing and price comparison, LSE:FUTR Future PLC stands out as a beacon of robust growth and potential. Founded in 1985 and headquartered in Bath, the United Kingdom, Future PLC has carved a niche for itself by publishing and distributing content across a spectrum of sectors including games, entertainment, technology, sports, and more. With its shares currently priced at an attractively low point, there’s a strong case to be made for considering Future PLC as a buy trade, with a current buy-in at 700 and ambitious targets of 1,400 and 2,100. Encouraging Performance and Strategic Growth Future PLC's recent first-half trading update has been met with optimism, described by analysts as "encouraging" and "broadly reassuring". The company has demonstrated a return to organic revenue growth, a testament to the effectiveness of its diversified business model that spans Media and Magazine segments. This rebound is particularly notable in its operations such as Go.Compare, B2B, and Magazines, despite the headwinds faced in affiliate products and digital advertising amid macroeconomic uncertainties. The stabilisation in website user trends and the initial progress of the Growth Acceleration Strategy (GAS) underscore the company's adaptive and forward-looking management approach. Analyst Jessica Pok from Panmure Gordon remarked on these developments as positive signs, highlighting the stock's attractive valuation at just 5 times FY25E PE. Valuation and Market Position One cannot overlook the compelling valuation metrics that underscore Future PLC's investment appeal. Currently trading at a PE ratio of just 6.9, the company is significantly undervalued when compared to the peer average of 11.8. This discrepancy not only points to the stock’s anomalously low price but also signals substantial upside potential. Should Future PLC’s PE ratio align with the sector average, the implications for its share price could be profound, elevating it well beyond its current level of 700. Moreover, based on a discounted cash flow model, Future PLC's fair value is estimated at 2,597, suggesting that the shares are currently 73.7% undervalued. This valuation presents a compelling case for the stock as a buy, with the current price offering a substantial margin of safety and an attractive entry point for investors seeking both growth and value. Looking Ahead As Future PLC continues to implement its strategic initiatives under the GAS, there is a keen anticipation of improved performance in affiliate and digital advertising revenues. This improvement, as broker Roddy Davidson at Shore Capital suggests, will be pivotal for a meaningful recovery in share price and for gaining traction across its growth strategies. The digital publishing and price comparison sectors are replete with challenges but also abundant with opportunities. Future PLC, with its diversified portfolio, strategic growth initiatives, and currently undervalued shares, presents an enticing prospect for investors looking to capitalise on these opportunities. Its low PE ratio, compared to peers, and the significant undervaluation based on fair value, all point to Future PLC not just as a stock to watch, but as a compelling buy in today's market. For investors and traders alike, the current valuation of Future PLC offers a rare convergence of growth prospects and value, making it a standout choice in the dynamic and competitive landscape of digital media and financial services.
LSE:FUTRLong
by Samuelleach